Compare AGM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | STOK |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | AGM | STOK |
|---|---|---|
| Price | $236.87 | $31.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $215.00 | $39.20 |
| AVG Volume (30 Days) | 112.0K | ★ 617.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | $77.49 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $136.57 | $12.86 |
| 52 Week High | $248.29 | $40.22 |
| Indicator | AGM | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 76.19 | 58.51 |
| Support Level | $166.78 | $30.34 |
| Resistance Level | N/A | $34.83 |
| Average True Range (ATR) | 7.46 | 1.64 |
| MACD | 2.75 | 0.30 |
| Stochastic Oscillator | 73.54 | 78.37 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.